BioRestorative Therapies (BRTX) Operating Expenses (2010 - 2025)

BioRestorative Therapies (BRTX) has reported Operating Expenses for 16 consecutive years, with $3.8 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses rose 40.77% year-over-year to $3.8 million; the trailing twelve-month figure through Dec 2025 stood at $16.0 million (up 33.99% YoY), and the FY2025 full-year result was $16.0 million, up 33.99% from the prior year.
• Operating Expenses advanced to $3.8 million in Q4 2025 per BRTX's latest filing, from $3.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $15.1 million in Q1 2021 and bottomed at $2.5 million in Q3 2024.
• Historically, Operating Expenses has averaged $4.4 million across 5 years, with a median of $3.8 million in 2025.
• The sharpest annual moves came in 2021 and 2022: Operating Expenses jumped 1683.77% in 2021, then sank 66.36% in 2022.
• Over 5 years, Operating Expenses stood at $4.0 million in 2021, then rose by 16.72% to $4.7 million in 2022, then tumbled by 30.85% to $3.2 million in 2023, then retreated by 15.74% to $2.7 million in 2024, then surged by 40.77% to $3.8 million in 2025.
• According to Business Quant data, Operating Expenses over the past three periods registered $3.8 million, $3.7 million, and $3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.